INT63341

From wiki-pain
Revision as of 08:49, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1996
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 42
Total Number 42
Disease Relevance 30.45
Pain Relevance 9.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (ICAM1) cell adhesion (ICAM1) plasma membrane (ICAM1)
Anatomy Link Frequency
bladder 2
synovial fluid 1
peritoneal macrophages 1
CD86 1
leukocytes 1
ICAM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 23 100.00 Very High Very High Very High
Infliximab 22 99.98 Very High Very High Very High
Inflammation 676 99.62 Very High Very High Very High
Migraine 50 99.24 Very High Very High Very High
dexamethasone 26 99.16 Very High Very High Very High
corticosteroid 8 98.60 Very High Very High Very High
rheumatoid arthritis 219 98.44 Very High Very High Very High
Nicotine 120 98.08 Very High Very High Very High
transdermal 24 95.76 Very High Very High Very High
withdrawal 5 94.40 High High
Disease Link Frequency Relevance Heat
Nicotine Addiction 2205 100.00 Very High Very High Very High
Adhesions 1239 100.00 Very High Very High Very High
Brain Injury 25 99.84 Very High Very High Very High
Bone Cancer 8 99.84 Very High Very High Very High
INFLAMMATION 787 99.62 Very High Very High Very High
Headache 52 99.24 Very High Very High Very High
Bladder Cancer 24 98.48 Very High Very High Very High
Rheumatoid Arthritis 223 98.44 Very High Very High Very High
Hyperlipoproteinemia Type Ii 10 97.88 Very High Very High Very High
Disease 410 97.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The mechanism of ICAM-1 downregulation was mainly post-transcriptional, but also partly transcriptional.
Negative_regulation (downregulation) of ICAM-1
1) Confidence 0.59 Published 1996 Journal Eur. Respir. J. Section Abstract Doc Link 8730005 Disease Relevance 0.25 Pain Relevance 0.26
Inhibition of ICAM-1 ameliorated these changes significantly.
Negative_regulation (Inhibition) of ICAM-1
2) Confidence 0.57 Published 2004 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 15308472 Disease Relevance 0.19 Pain Relevance 0
So far, clinical studies on ICAM-1 blockade in bone diseases have been limited to RA.
Negative_regulation (blockade) of ICAM-1 associated with rheumatoid arthritis and bone cancer
3) Confidence 0.50 Published 2005 Journal Expert Opin Biol Ther Section Abstract Doc Link 15833069 Disease Relevance 1.27 Pain Relevance 0.31
ICAM-1 blockade between the Ob and the pre-Oc results in an inhibition of Oc recruitment and a modulation of inflammation, which could potentially help in controlling disease activity in bone pathologies.
Negative_regulation (blockade) of ICAM-1 associated with inflammation and disease
4) Confidence 0.50 Published 2005 Journal Expert Opin Biol Ther Section Abstract Doc Link 15833069 Disease Relevance 1.24 Pain Relevance 0.31
In contrast patients not eligible for thrombolytic therapy and therefore treated with conventional therapy (a continuous i.v. infusion of nitroglycerin at the dose of 50 mg/die) did not show any significant reduction in both sE-selectin and sICAM-1 throughout the study.
Negative_regulation (reduction) of sICAM-1
5) Confidence 0.50 Published 1996 Journal Inflamm. Res. Section Abstract Doc Link 8821773 Disease Relevance 0.80 Pain Relevance 0.09
-tocopherol (2 years at 400 IU dL/day). sICAM-1 levels were reduced in healthy men by glucocorticoid (dexamethasone) treatment [179].


Negative_regulation (reduced) of sICAM-1 associated with dexamethasone
6) Confidence 0.50 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 0.62 Pain Relevance 0.11
-tocopherol (2 years at 400 IU dL/day). sICAM-1 levels were reduced in healthy men by glucocorticoid (dexamethasone) treatment [179].


Negative_regulation (reduced) of sICAM-1 associated with dexamethasone
7) Confidence 0.50 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 0.62 Pain Relevance 0.11
The decline in sICAM-1 levels noted on cessation is not compromised by high-dosage nicotine replacement therapy, in the form of transdermal nicotine patches (unpublished data).
Negative_regulation (decline) of sICAM-1 associated with transdermal and nicotine
8) Confidence 0.50 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 0.95 Pain Relevance 0.23
The decline in sICAM-1 levels noted on cessation is not compromised by high-dosage nicotine replacement therapy, in the form of transdermal nicotine patches (unpublished data).
Negative_regulation (decline) of sICAM-1 associated with transdermal and nicotine
9) Confidence 0.50 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 0.95 Pain Relevance 0.23
Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients.
Negative_regulation (Inhibition) of intercellular adhesion molecule-1 associated with migraine and adhesions
10) Confidence 0.45 Published 1997 Journal J. Mol. Med. Section Title Doc Link 9231885 Disease Relevance 1.01 Pain Relevance 0.68
Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients.
Negative_regulation (Inhibition) of ICAM-1 associated with migraine and adhesions
11) Confidence 0.45 Published 1997 Journal J. Mol. Med. Section Title Doc Link 9231885 Disease Relevance 1.01 Pain Relevance 0.69
The demonstration in the current study that ICAM-1 levels are equivalent in the endometrial endothelium of specimens from the E2-dominated follicular phase, the progesterone-exposed luteal phase, and the steroid-withdrawal-initiated menstrual phase suggests that ICAM-1 expression is not under direct ovarian steroid regulation.
Negative_regulation (equivalent) of ICAM in endothelium associated with withdrawal
12) Confidence 0.43 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1403781 Disease Relevance 0.10 Pain Relevance 0.05
By blocking the ICAM-1 receptors, HA presumably alleviates the inflammatory processes, but repeated instillations are needed to maintain the response.


Negative_regulation (blocking) of ICAM
13) Confidence 0.43 Published 2002 Journal Urology Section Body Doc Link 12100920 Disease Relevance 0 Pain Relevance 0
Thus, ICAM-1 molecules are inhibited in their passage from the periodontal microvasculature or through the periodontal tissues.
Negative_regulation (inhibited) of ICAM-1
14) Confidence 0.42 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 1.06 Pain Relevance 0
Thus, ICAM-1 molecules are inhibited in their passage from the periodontal microvasculature or through the periodontal tissues.
Negative_regulation (inhibited) of ICAM-1
15) Confidence 0.42 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 1.06 Pain Relevance 0
Young et al. [187] purified sICAM-1 from normal human serum and the urine of patients with bladder cancer by immunoaffinity chromatography and detected only monomeric sICAM-1, which could not block LFA-1/ICAM-1-dependent cell-mediated cytolosis of bladder tumour target cells.
Negative_regulation (block) of ICAM-1 in bladder associated with bladder cancer
16) Confidence 0.41 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 0.31 Pain Relevance 0.03
Young et al. [187] purified sICAM-1 from normal human serum and the urine of patients with bladder cancer by immunoaffinity chromatography and detected only monomeric sICAM-1, which could not block LFA-1/ICAM-1-dependent cell-mediated cytolosis of bladder tumour target cells.
Negative_regulation (block) of ICAM-1 in bladder associated with bladder cancer
17) Confidence 0.41 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 0.31 Pain Relevance 0.03
Efalizumab inhibits T-cell activation, cutaneous trafficking, and adhesion to keratinocytes through the blockade of LFA-1/ICAM-1 binding, steps in the immunologic cascade that lead to the formation of the psoriatic plaques (Menter et al 2005).
Negative_regulation (blockade) of ICAM-1 in plaques associated with psoriasis and adhesions
18) Confidence 0.41 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727906 Disease Relevance 0.74 Pain Relevance 0.07
B1 p50 oligonucleotides exhibited a moderate inhibitory effect on expression of ICAM-1 in HCPSMC but no effect in HCMSMC.
Negative_regulation (effect) of ICAM-1
19) Confidence 0.39 Published 2001 Journal BMC Mol Biol Section Body Doc Link PMC48145 Disease Relevance 0 Pain Relevance 0
Thrombolytic therapy with urokinase (1,000,000 IU as an intravenous bolus for 5 minutes, followed by an infusion of an additional 1,000,000 IU for the following two hours) succeeded in producing reperfusion and reduced the serum levels of sE-selectin (52 +/- 13 ng/ml) and sICAM-1 (202 +/- 31 ng/ml).
Negative_regulation (reduced) of sICAM-1
20) Confidence 0.37 Published 1996 Journal Inflamm. Res. Section Abstract Doc Link 8821773 Disease Relevance 1.03 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox